Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Junshi Bio Stages $692 Million IPO on Shanghai's STAR Board

publication date: Jul 16, 2020

Shanghai Junshi Biosciences completed a $692 million IPO on the Shanghai STAR Board, becoming the first biopharma to have a dual listing on the Hong Kong and STAR Exchanges. Junshi staged a $394 million Hong Kong IPO in late 2018, about the same time the company's Tuoyi became the first China-developed anti-PD-1 approved for China use. Benefiting from strong demand, Junshi significantly increased the size of its STAR debut offering from an original $400 million. More details....

Stock Symbols: (SHA: 688180; HK: 1877)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.